# Wee-Joo Chng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8415870/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 313 papers | 15,696 citations | 28190 55 h-index | 19690 117 g-index |
| 317 all docs | 317 docs citations | 317 times ranked | 19484 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346. | 5.1 | 1,866 |
| 2 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748. | 3.3 | 1,023 |
| 3 | Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144. | 7.7 | 941 |
| 4 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38. | 5.1 | 723 |
| 5 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962. | 0.6 | 686 |
| 6 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157. | 3.3 | 664 |
| 7 | A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 2012, 18, 521-528. | 15.2 | 510 |
| 8 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology, The, 2017, 18, e206-e217. | 5.1 | 394 |
| 9 | AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180. | 7.7 | 322 |
| 10 | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1327-1337. | 5.1 | 320 |
| 11 | Telomerase directly regulates NF-ÎºB-dependent transcription. Nature Cell Biology, 2012, 14, 1270-1281. | 4.6 | 309 |
| 12 | A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 389-400. | 5.1 | 285 |
| 13 | p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation. World Journal of Gastroenterology, 2015, 21, 84. | 1.4 | 248 |
| 14 | Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood, 2018, 132, 1146-1158. | 0.6 | 218 |
| 15 | The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood, 2011, 118, 2830-2839. | 0.6 | 205 |
| 16 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, 2015, 125, 443-448. | 0.6 | 195 |
| 17 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264. | 6.3 | 187 |
| 18 | T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing. Cancer Research, 2014, 74, 93-103. | 0.4 | 171 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Enabling Technologies for Personalized and Precision Medicine. Trends in Biotechnology, 2020, 38, 497-518. | 4.9 | 169 |
| 20 | PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase. Cancer Cell, 2010, 18, 52-62. | 7.7 | 155 |
| 21 | Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood, 2009, 113, 4052-4062. | 0.6 | 144 |
| 22 | Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-Î¹B regulated gene products in multiple myeloma xenograft mouse model. Oncotarget, 2014, 5, 634-648. | 0.8 | 142 |
| 23 | LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. International Journal of Biochemistry and Cell Biology, 2013, 45, 973-978. | 1.2 | 140 |
| 24 | Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion, 2013, 13, 163-169. | 1.6 | 137 |
| 25 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118. | 5.1 | 136 |
| 26 | Type II enteropathyâ€associated Tâ€cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. American Journal of Hematology, 2012, 87, 663-668. | 2.0 | 134 |
| 27 | EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood, 2013, 121, 4512-4520. | 0.6 | 131 |
| 28 | Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore. Nature Biotechnology, 2021, 39, 1394-1402. | 9.4 | 131 |
| 29 | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-Î¹B and STAT3 regulated gene products in multiple myeloma cells. British Journal of Pharmacology, 2011, 164, 1506-1521. | 2.7 | 120 |
| 30 | EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood, 2016, 128, 948-958. | 0.6 | 110 |
| 31 | CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer Journal, 2021, 11, 84. | 2.8 | 97 |
| 32 | TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms. International Journal of Biochemistry and Cell Biology, 2011, 43, 1668-1673. | 1.2 | 94 |
| 33 | The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers, 2018, 10, 327. | 1.7 | 94 |
| 34 | Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target. Oncotarget, 2015, 6, 5490-5500. | 0.8 | 92 |
| 35 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, 2017, 130, 2610-2618. | 0.6 | 90 |
| 36 | Clinical profiles of multiple myeloma in Asiaâ€"An Asian Myeloma Network study. American Journal of Hematology, 2014, 89, 751-756. | 2.0 | 88 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multiple myelomaâ€“associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. Journal of Clinical Investigation, 2012, 122, 2793-2806. | 3.9 | 87 |
| 38 | Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology, The, 2016, 17, 1240-1247. | 5.1 | 84 |
| 39 | Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry, 2017, 60, 8336-8357. | 2.9 | 82 |
| 40 | Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica, 2018, 103, 278-287. | 1.7 | 82 |
| 41 | Molecular pathogenic pathways in extranodal NK/T cell lymphoma. Journal of Hematology and Oncology, 2019, 12, 33. | 6.9 | 82 |
| 42 | Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14402-14407. | 3.3 | 81 |
| 43 | Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Science Translational Medicine, 2018, 10, . | 5.8 | 80 |
| 44 | Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. Journal of Medicinal Chemistry, 2016, 59, 8233-8262. | 2.9 | 78 |
| 45 | Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17. | 2.8 | 75 |
| 46 | Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 1-12. | 2.1 | 73 |
| 47 | NanoVar: accurate characterization of patientsâ€™ genomic structural variants using low-depth nanopore sequencing. Genome Biology, 2020, 21, 56. | 3.8 | 73 |
| 48 | Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. Journal of Hematology and Oncology, 2019, 12, 77. | 6.9 | 69 |
| 49 | International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30. | 3.3 | 69 |
| 50 | Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood, 2018, 132, 1304-1317. | 0.6 | 67 |
| 51 | HIFI-Î± activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3735-44. | 3.3 | 62 |
| 52 | EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. Journal of Hematology and Oncology, 2019, 12, 118. | 6.9 | 62 |
| 53 | Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. Journal of Clinical Investigation, 2013, 123, 3459-3471. | 3.9 | 62 |
| 54 | VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics, 2013, 12, 151-161. | 1.9 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy. PLoS ONE, 2011, 6, e19798. | 1.1 | 59 |
| 56 | ATM-dependent spontaneous regression of early Eî¼-mycâ€“induced murine B-cell leukemia depends on natural killer and T cells. Blood, 2013, 121, 2512-2521. | 0.6 | 56 |
| 57 | Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World Journal of Stem Cells, 2014, 6, 473. | 1.3 | 55 |
| 58 | STAT3: A Promising Therapeutic Target in Multiple Myeloma. Cancers, 2019, 11, 731. | 1.7 | 54 |
| 59 | IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. Cancer Research, 2019, 79, 4679-4688. | 0.4 | 53 |
| 60 | Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncology, The, 2020, 21, 306-316. | 5.1 | 49 |
| 61 | An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020, 135, 2337-2353. | 0.6 | 49 |
| 62 | Tumor-derived exosomes in colorectal cancer progression and their clinical applications. Oncotarget, 2017, 8, 100781-100790. | 0.8 | 48 |
| 63 | Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3534-3539. | 3.3 | 47 |
| 64 | Deregulated <scp>MIR</scp>335 that targets <scp>MAPK</scp>1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2013, 163, 93-103. | 1.2 | 46 |
| 65 | MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1750-1760. | 1.9 | 46 |
| 66 | Oncogenic roles of <scp>PRL</scp>â€3 in <scp>FLT</scp>3â€<scp>ITD</scp> induced acute myeloid leukaemia. EMBO Molecular Medicine, 2013, 5, 1351-1366. | 3.3 | 44 |
| 67 | MicroRNA: Important Player in the Pathobiology of Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12. | 0.9 | 43 |
| 68 | Large-scale expansion of Vî³9Vî´2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptorâ€“modified effector cells. Cytotherapy, 2018, 20, 420-435. | 0.3 | 43 |
| 69 | ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica, 2020, 105, 2286-2297. | 1.7 | 43 |
| 70 | Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. Oncotarget, 2012, 3, 158-171. | 0.8 | 42 |
| 71 | A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. PLoS ONE, 2013, 8, e66361. | 1.1 | 41 |
| 72 | Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget, 2015, 6, 26508-26518. | 0.8 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Towards understanding of PRC2 binding to RNA. RNA Biology, 2019, 16, 176-184. | 1.5 | 40 |
| 74 | PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget, 2015, 6, 36689-36699. | 0.8 | 39 |
| 75 | CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. Cancer Gene Therapy, 2022, 29, 475-483. | 2.2 | 38 |
| 76 | Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival. Oncotarget, 2013, 4, 1230-1240. | 0.8 | 38 |
| 77 | Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1507-1514. | 1.2 | 37 |
| 78 | Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e571-e581. | 5.1 | 37 |
| 79 | Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investigation, 2017, 4, 6-6. | 1.3 | 36 |
| 80 | Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies. Trends in Pharmacological Sciences, 2019, 40, 897-910. | 4.0 | 35 |
| 81 | Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma. Cellular and Molecular Life Sciences, 2021, 78, 3883-3906. | 2.4 | 35 |
| 82 | IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica, 2020, 105, 1391-1404. | 1.7 | 34 |
| 83 | The emerging roles of exosomes in leukemogeneis. Oncotarget, 2016, 7, 50698-50707. | 0.8 | 33 |
| 84 | Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European Journal of Medicinal Chemistry, 2018, 158, 593-619. | 2.6 | 33 |
| 85 | Curcumin Sensitizes Acute Promyelocytic Leukemia Cells to Unfolded Protein Responseâ€“Induced Apoptosis by Blocking the Loss of Misfolded N-CoR Protein. Molecular Cancer Research, 2011, 9, 878-888. | 1.5 | 32 |
| 86 | Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica, 2019, 104, 1209-1220. | 1.7 | 30 |
| 87 | Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells. PLoS ONE, 2011, 6, e21583. | 1.1 | 29 |
| 88 | LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia. Cancer Research, 2014, 74, 3043-3053. | 0.4 | 29 |
| 89 | LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cellâ€“like Transcriptional Program in AML. Molecular Cancer Research, 2017, 15, 294-303. | 1.5 | 29 |
| 90 | The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. International Journal of Molecular Sciences, 2018, 19, 1931. | 1.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Targeted Therapy in Multiple Myeloma. Cancer Control, 2005, 12, 91-104. | 0.7 | 27 |
| 92 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs, 2015, 33, 942-953. | 1.2 | 27 |
| 93 | Immunotherapy in Multiple Myeloma. Cells, 2020, 9, 601. | 1.8 | 27 |
| 94 | Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250. | 0.6 | 27 |
| 95 | Bimodal Influence of Vitamin D in Host Response to SystemicCandidaInfectionâ€"Vitamin D Dose Matters. Journal of Infectious Diseases, 2015, 212, 635-644. | 1.9 | 26 |
| 96 | Chromatin interaction neural network (ChINN): a machine learning-based method for predicting chromatin interactions from DNA sequences. Genome Biology, 2021, 22, 226. | 3.8 | 26 |
| 97 | Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma. Oncotarget, 2013, 4, 1008-1018. | 0.8 | 26 |
| 98 | MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. Blood, 2019, 134, 2046-2058. | 0.6 | 25 |
| 99 | Rapid production of clinicalâ€grade SARSâ€CoVâ€2 specific T cells. Advances in Cell and Gene Therapy, 2020, 3, e101. | 0.6 | 24 |
| 100 | Targeting NF-Îº B Signaling for Multiple Myeloma. Cancers, 2020, 12, 2203. | 1.7 | 24 |
| 101 | Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284. | 2.6 | 24 |
| 102 | Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip. Npj Precision Oncology, 2019, 3, 30. | 2.3 | 23 |
| 103 | PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget, 2016, 7, 61806-61819. | 0.8 | 23 |
| 104 | Establishment and Characterization of Novel Human Primary and Metastatic Anaplastic Thyroid Cancer Cell Lines and Their Genomic Evolution Over a Year as a Primagraft. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 725-735. | 1.8 | 22 |
| 105 | Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 2017, 58, 2501-2504. | 0.6 | 22 |
| 106 | A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/Î²-catenin pathways for treatment of AML with high PRL-3 phosphatase. Journal of Hematology and Oncology, 2018, 11, 36. | 6.9 | 22 |
| 107 | Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer Journal, 2020, 10, 9. | 2.8 | 22 |
| 108 | In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. Journal of Controlled Release, 2012, 160, 290-298. | 4.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | MMSET: Role and Therapeutic Opportunities in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-5. | 0.9 | 21 |
| 110 | Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. Experimental Hematology, 2014, 42, 1041-1052.e2. | 0.2 | 21 |
| 111 | Risk Stratification in Multiple Myeloma. Current Hematologic Malignancy Reports, 2016, 11, 137-147. | 1.2 | 21 |
| 112 | The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations. Cytometry Part B - Clinical Cytometry, 2018, 94, 159-168. | 0.7 | 21 |
| 113 | High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS ONE, 2015, 10, e0142466. | 1.1 | 19 |
| 114 | Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leukemia and Lymphoma, 2018, 59, 2305-2317. | 0.6 | 18 |
| 115 | Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS ONE, 2015, 10, e0122983. | 1.1 | 18 |
| 116 | Super Enhancer-Mediated Upregulation ofHJURPPromotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. Cancer Research, 2022, 82, 406-418. | 0.4 | 18 |
| 117 | Non-canonical activation of Î²-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene, 2019, 38, 1508-1519. | 2.6 | 17 |
| 118 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027. | 3.3 | 17 |
| 119 | High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer Journal, 2021, 11, 143. | 2.8 | 17 |
| 120 | Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. Cancer Letters, 2014, 354, 272-280. | 3.2 | 16 |
| 121 | BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia. BMC Cancer, 2018, 18, 731. | 1.1 | 16 |
| 122 | Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget, 2016, 7, 74779-74796. | 0.8 | 16 |
| 123 | Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World Journal of Clinical Oncology, 2018, 9, 90-97. | 0.9 | 16 |
| 124 | Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer Journal, 2022, 12, 24. | 2.8 | 16 |
| 125 | The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leukemia Research, 2013, 37, 1070-1076. | 0.4 | 15 |
| 126 | Necrotizing Fasciitis in Hematological Patients: Enterobacteriaceae Predominance and Limited Utility of Laboratory Risk Indicator for Necrotizing Fasciitis Score. Open Forum Infectious Diseases, 2015, 2, ofv081. | 0.4 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Xâ€linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to <scp>TRAIL</scp> and chemotherapy through potentiated induction of proapoptotic machinery. Molecular Oncology, 2018, 12, 33-47. | 2.1 | 15 |
| 128 | CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay. Journal of Clinical Pathology, 2018, 71, 522-531. | 1.0 | 15 |
| 129 | Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. European Journal of Medicinal Chemistry, 2019, 184, 111755. | 2.6 | 15 |
| 130 | Immunoglobulin M Paraproteinaemias. Cancers, 2020, 12, 1688. | 1.7 | 15 |
| 131 | Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103211. | 2.0 | 15 |
| 132 | Daratumumab Resistant Natural Killer/T-Cell Lymphoma Exhibit an Addiction to the Exosome Biogenesis Pathway for Survival. Blood, 2021, 138, 2256-2256. | 0.6 | 15 |
| 133 | ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia. Cellular and Molecular Life Sciences, 2018, 75, 3931-3941. | 2.4 | 14 |
| 134 | Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia, 2021, 35, 1797-1802. | 3.3 | 14 |
| 135 | Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. Blood Cancer Journal, 2021, 11, 32. | 2.8 | 14 |
| 136 | Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Molecular Cancer Therapeutics, 2021, 20, 1702-1712. | 1.9 | 14 |
| 137 | Translocation (8;22) in cold agglutinin disease associatedwith B-cell lymphoma. Cancer Genetics and Cytogenetics, 2004, 152, 66-69. | 1.0 | 13 |
| 138 | Single-cell genomic profiling of acute myeloid leukemia for clinical use: A pilot study. Oncology Letters, 2017, 13, 1625-1630. | 0.8 | 13 |
| 139 | MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia, 2019, 33, 739-748. | 3.3 | 13 |
| 140 | Microenvironmental Hypoxia Induces Dynamic Changes in Lung Cancer Synthesis and Secretion of Extracellular Vesicles. Cancers, 2020, 12, 2917. | 1.7 | 13 |
| 141 | LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget, 2018, 9, 31832-31841. | 0.8 | 13 |
| 142 | Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. International Journal of Hematology, 2019, 110, 466-473. | 0.7 | 12 |
| 143 | Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS ONE, 2020, 15, e0232068. | 1.1 | 12 |
| 144 | Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer Progression. Frontiers in Oncology, 2021, 11, 559822. | 1.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells. Haematologica, 2022, 107, 680-689. | 1.7 | 12 |
| 146 | The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. Npj Digital Medicine, 2022, 5, . | 5.7 | 11 |
| 147 | Modified clg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice. Cancer Genetics, 2014, 207, 31-34. | 0.2 | 10 |
| 148 | Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma. Experimental Hematology and Oncology, 2020, 9, 8. | 2.0 | 10 |
| 149 | ADARs, RNA editing and more in hematological malignancies. Leukemia, 2021, 35, 346-359. | 3.3 | 10 |
| 150 | SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma. Cancer Research, 2021, 81, 2332-2344. | 0.4 | 10 |
| 151 | Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World Journal of Clinical Oncology, 2019, 10, 303-306. | 0.9 | 10 |
| 152 | Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Annals of Hematology, 2019, 98, 941-949. | 0.8 | 9 |
| 153 | Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301. | 0.6 | 9 |
| 154 | Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. Blood, 2012, 120, 76-76. | 0.6 | 9 |
| 155 | Role of Misfolded N-CoR Mediated Transcriptional Deregulation of Flt3 in Acute Monocytic Leukemia (AML)-M5 Subtype. PLoS ONE, 2012, 7, e34501. | 1.1 | 8 |
| 156 | CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells. British Journal of Haematology, 2014, 165, 134-144. | 1.2 | 8 |
| 157 | Qualitative Study of Factors Affecting Patient, Caregiver and Physician Preferences for Treatment of Myeloma and Indolent Lymphoma . Patient Preference and Adherence, 2020, Volume 14, 301-308. | 0.8 | 8 |
| 158 | Recommendations to improve the clinical adoption of NGSâ€based cancer diagnostics in Singapore. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 222-231. | 0.7 | 8 |
| 159 | Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. , 2021, 9, e002123. | | 8 |
| 160 | Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). Blood, 2015, 126, 30-30. | 0.6 | 8 |
| 161 | Surgical Management of Multiple Myeloma With Symptomatic Involvement of the Spine. International Journal of Spine Surgery, 2020, 14, 785-794. | 0.7 | 8 |
| 162 | NF-ÎºB promotes the stem-like properties of leukemia cells by activation of LIN28B. World Journal of Stem Cells, 2018, 10, 34-42. | 1.3 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature.. Blood, 2005, 106, 1538-1538. | 0.6 | 8 |
| 164 | Unusual case of metachronous EBVâ€associated Bâ€cell and NK/Tâ€cell lymphoma mimicking polymyositisâ€diagnostic challenges and pitfalls. American Journal of Hematology, 2014, 89, 110-113. | 2.0 | 7 |
| 165 | Epsteinâ€“Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype. Leukemia and Lymphoma, 2015, 56, 2408-2415. | 0.6 | 7 |
| 166 | circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. Haematologica, 2020, 105, e343-e348. | 1.7 | 7 |
| 167 | Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled PhaseÂ3 Studyâ€”Asian Subgroup Analysis. Advances in Therapy, 2020, 37, 3404-3416. | 1.3 | 7 |
| 168 | Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Singapore Medical Journal, 2012, 53, 720-5. | 0.3 | 7 |
| 169 | Molecular switch of EZH2 in hypoxia. Cell Cycle, 2016, 15, 3007-3008. | 1.3 | 6 |
| 170 | Neutrophils differentially attenuate immune response toAspergillusinfection through complement receptor 3 and induction of myeloperoxidase. Cellular Microbiology, 2018, 20, e12798. | 1.1 | 6 |
| 171 | Carfilzomibâ€“dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma, 2018, 59, 1364-1374. | 0.6 | 6 |
| 172 | Macrophages protect mycoplasmaâ€infected chronic myeloid leukemia cells from natural killer cell killing. Immunology and Cell Biology, 2020, 98, 138-151. | 1.0 | 6 |
| 173 | The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Medical Journal, 2017, 58, 55-71. | 0.3 | 6 |
| 174 | Metabolic Vulnerabilities in Multiple Myeloma. Cancers, 2022, 14, 1905. | 1.7 | 6 |
| 175 | Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. Supportive Care in Cancer, 2014, 22, 1447-1451. | 1.0 | 5 |
| 176 | VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. Oncotarget, 2017, 8, 101847-101864. | 0.8 | 5 |
| 177 | Potential Clinical Application of Genomics in Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 1721. | 1.8 | 5 |
| 178 | Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. International Journal of Antimicrobial Agents, 2018, 52, 350-357. | 1.1 | 5 |
| 179 | Lymphocyte cytosolic protein 1 (LCP1) is a novel TRAF3 dysregulation biomarker with potential prognostic value in multiple myeloma. Genome Instability & Disease, 2020, 1, 286-299. | 0.5 | 5 |
| 180 | RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene, 2021, 40, 746-762. | 2.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity. Blood, 2018, 132, 2676-2676. | 0.6 | 5 |
| 182 | Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Blood, 2015, 126, 1844-1844. | 0.6 | 5 |
| 183 | Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas. Oncotarget, 2016, 7, 83964-83975. | 0.8 | 5 |
| 184 | Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma. Cells, 2022, 11, 941. | 1.8 | 5 |
| 185 | VÎ³9VÎ´2 T cells expressing a BCMAâ€"Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS ONE, 2022, 17, e0267475. | 1.1 | 5 |
| 186 | Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. Frontiers in Oncology, 0, 12, . | 1.3 | 5 |
| 187 | Carfilozomib versus bortezomib for relapsed or refractory myeloma â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e126. | 5.1 | 4 |
| 188 | Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Biology of Blood and Marrow Transplantation, 2019, 25, S19-S20. | 2.0 | 4 |
| 189 | Akt-Induced Phosphorylation of N-CoR at Serine 1450 Contributes to Its Misfolded Conformational Dependent Loss (MCDL) in Acute Myeloid Leukemia of the M5 Subtype. PLoS ONE, 2013, 8, e70891. | 1.1 | 4 |
| 190 | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. Cancers, 2021, 13, 5147. | 1.7 | 4 |
| 191 | Bivalent Histone Modifications By Reiibp Leads to Transcriptional Reprogramming and TLR7-BTK Driven IL-6 Pro-Inflammatory Response in t(4;14) Myelomagenesis. Blood, 2021, 138, 2202-2202. | 0.6 | 4 |
| 192 | THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. International Journal of Molecular Sciences, 2022, 23, 1207. | 1.8 | 4 |
| 193 | A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of VÎ³9VÎ´2 T cells. Immunotherapy, 2022, 14, 321-336. | 1.0 | 4 |
| 194 | New immunotherapeutic target in myeloma. Blood, 2022, 139, 2417-2418. | 0.6 | 4 |
| 195 | Castlemanâ€™s Disease Presenting as Prolonged Anemia and Growth Retardation: A Case Report and Literature Review. Acta Haematologica, 2011, 125, 125-129. | 0.7 | 3 |
| 196 | Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 225-232. | 0.6 | 3 |
| 197 | Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e470-e477. | 0.2 | 3 |
| 198 | Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e165-e170. | 0.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | CD55 and CD59 Can Limit the Anti-Tumor Efficacy of Daratumumab in Natural Killer/T-Cell Lymphoma. Blood, 2018, 132, 1663-1663. | 0.6 | 3 |
| 200 | Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.. Blood, 2006, 108, 132-132. | 0.6 | 3 |
| 201 | ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. Blood, 2011, 118, 88-88. | 0.6 | 3 |
| 202 | The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. Blood, 2015, 126, 3737-3737. | 0.6 | 3 |
| 203 | Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201. | 0.6 | 3 |
| 204 | Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). Blood, 2015, 126, 729-729. | 0.6 | 3 |
| 205 | Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 167, 103507. | 2.0 | 3 |
| 206 | Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP).. Blood, 2008, 112, 1673-1673. | 0.6 | 3 |
| 207 | Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer/T-Cell Lymphoma. Blood, 2011, 118, 2637-2637. | 0.6 | 3 |
| 208 | p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). Oncogene, 2022, 41, 2106-2121. | 2.6 | 3 |
| 209 | Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. Cancer Biology and Therapy, 2016, 17, 723-726. | 1.5 | 2 |
| 210 | Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. British Journal of Haematology, 2019, 186, 162-165. | 1.2 | 2 |
| 211 | Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Cancers, 2020, 12, 1759. | 1.7 | 2 |
| 212 | Daratumumabâ€induced transient myopic shift and its proposed mechanisms. Clinical and Experimental Ophthalmology, 2021, 49, 81-83. | 1.3 | 2 |
| 213 | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Blood Cancer Journal, 2021, 11, 150. | 2.8 | 2 |
| 214 | Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report. Blood, 2018, 132, 5237-5237. | 0.6 | 2 |
| 215 | Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.. Blood, 2005, 106, 508-508. | 0.6 | 2 |
| 216 | Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM).. Blood, 2006, 108, 109-109. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines.. Blood, 2007, 110, 2489-2489. | 0.6 | 2 |
| 218 | A Rare Variant of Aggressive T-Cell Large Granular Lymphocyte Leukemia Associated With Hepatic Fibrosis and Trisomy 8: A Case Report and Literature Review. Journal of Hematology (Brossard,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69 | 0.4 | 2 |
| 219 | Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM). Blood, 2021, 138, 1656-1656. | 0.6 | 2 |
| 220 | Mapbatch: Conservative Batch Normalization for Single Cell RNA-Sequencing Data Enables Discovery of Rare Cell Populations in a Multiple Myeloma Cohort. Blood, 2021, 138, 2954-2954. | 0.6 | 2 |
| 221 | Isochromosome 17q; A Novel Finding in Myeloid Sarcoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 130-134. | 0.3 | 1 |
| 222 | Synthetic lethality in multiple myeloma harboring double oncogenic hits of 17p13(del) and 1q21(amp). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e50-e51. | 0.2 | 1 |
| 223 | Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone. Blood, 2019, 134, 4376-4376. | 0.6 | 1 |
| 224 | PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.. Blood, 2007, 110, 671-671. | 0.6 | 1 |
| 225 | Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.. Blood, 2008, 112, 1663-1663. | 0.6 | 1 |
| 226 | C3aR1 Contributed to Acute Myeloid Leukemia Acquired Resistance to ABT-737 and Involved In the Process of AML. Blood, 2011, 118, 1435-1435. | 0.6 | 1 |
| 227 | A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma. Blood, 2011, 118, 1824-1824. | 0.6 | 1 |
| 228 | Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. Journal of Clinical Oncology, 2012, 30, 8097-8097. | 0.8 | 1 |
| 229 | Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. Blood, 2005, 106, 624-624. | 0.6 | 1 |
| 230 | Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma.. Blood, 2006, 108, 113-113. | 0.6 | 1 |
| 231 | Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma.. Blood, 2007, 110, 392-392. | 0.6 | 1 |
| 232 | Epidemiology of Patients with Classical Philadelphia-Chromosome Negative Myeloproliferative Neoplasms at a Single Academic Medical Center in Singapore. Blood, 2018, 132, 5478-5478. | 0.6 | 1 |
| 233 | Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma. Blood, 2019, 134, 362-362. | 0.6 | 1 |
| 234 | Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1358-1358. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3776-3776. | 0.6 | 1 |
| 236 | Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma. Blood, 2020, 136, 17-17. | 0.6 | 1 |
| 237 | Effects of a Mindfulness Program on Stress and Psychological Outcomes Among Cancer Survivors: a Quasi-Experimental Study. Mindfulness, 2022, 13, 982. | 1.6 | 1 |
| 238 | Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges. International Journal of Hematologic Oncology, 2012, 1, 133-146. | 0.7 | 0 |
| 239 | Role of HIFS & ARG2 in hematological malignancy. Experimental Hematology, 2015, 43, S84. | 0.2 | 0 |
| 240 | Transplant Outcomes and Early Relapse after Novel and Non-Novel Agent Induction: An Analysis By Singapore Myeloma Working Group. Biology of Blood and Marrow Transplantation, 2016, 22, S221. | 2.0 | 0 |
| 241 | Paraprotein interference in the diagnosis of hepatitis C infection. Clinical Chemistry and Laboratory Medicine, 2018, 56, e194-e196. | 1.4 | 0 |
| 242 | Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S248-S249. | 0.2 | 0 |
| 243 | NOVEL ROLE OF PRL-3 PHOSPHATASE IN HEMATOLOGICAL MALIGNANCIES. Experimental Hematology, 2019, 76, S67. | 0.2 | 0 |
| 244 | Salsalate is An Active Agent in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e135. | 0.2 | 0 |
| 245 | Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e274-e275. | 0.2 | 0 |
| 246 | Super-enhancer profiling of multiple myeloma in search of novel oncogenes and therapeutic targets. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e67-e68. | 0.2 | 0 |
| 247 | Single cell multiomic analysis and immune cell type profiling of multiple myeloma with t(4;14).. Journal of Clinical Oncology, 2021, 39, e20013-e20013. | 0.8 | 0 |
| 248 | A unique rhinologic manifestation of multiple myeloma. Otolaryngology Case Reports, 2021, 19, 100296. | 0.0 | 0 |
| 249 | Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM).. Blood, 2005, 106, 1539-1539. | 0.6 | 0 |
| 250 | Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes.. Blood, 2005, 106, 3006-3006. | 0.6 | 0 |
| 251 | Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma.. Blood, 2005, 106, 5102-5102. | 0.6 | 0 |
| 252 | Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma.. Blood, 2005, 106, 1537-1537. | 0.6 | 0 |
| 254 | Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells.. Blood, 2005, 106, 1555-1555. | 0.6 | 0 |
| 255 | Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms.. Blood, 2005, 106, 3480-3480. | 0.6 | 0 |
| 256 | One Half of Patients with Waldenstroì̂m Macroglobulinemia Have Large Deletions of Chromosome 6q.. Blood, 2005, 106, 1546-1546. | 0.6 | 0 |
| 257 | High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.. Blood, 2006, 108, 2093-2093. | 0.6 | 0 |
| 258 | Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587. | 0.6 | 0 |
| 259 | A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma.. Blood, 2006, 108, 3388-3388. | 0.6 | 0 |
| 260 | Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.. Blood, 2007, 110, 396-396. | 0.6 | 0 |
| 261 | Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.. Blood, 2007, 110, 2491-2491. | 0.6 | 0 |
| 262 | RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.. Blood, 2007, 110, 2478-2478. | 0.6 | 0 |
| 263 | Identification of Vacuolar H+- ATPase as a Target for Myeloma Therapeutics.. Blood, 2007, 110, 257-257. | 0.6 | 0 |
| 264 | High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.. Blood, 2007, 110, 4763-4763. | 0.6 | 0 |
| 265 | Waldenstroì̂m Macroglobulinaemia: The Impact of Cytogenetic Analysis.. Blood, 2007, 110, 2490-2490. | 0.6 | 0 |
| 266 | Comparative High Resolution Array-Based CGH (aCGH) in B-Cell Malignancies.. Blood, 2007, 110, 2479-2479. | 0.6 | 0 |
| 267 | Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.. Blood, 2008, 112, 1618-1618. | 0.6 | 0 |
| 268 | Recurrent Chromosome Abnormalities Define Non-Overlapping, Unique Subgroups of Tumors in Chronic Lymphocytic Leukemia Patients with Known Karyotypic Abnormalities. Blood, 2008, 112, 4176-4176. | 0.6 | 0 |
| 269 | Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.. Blood, 2008, 112, 1682-1682. | 0.6 | 0 |
| 270 | Gene Expression Profiling of Post-Follicular B-Cell Lymphoma. Blood, 2008, 112, 617-617. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Gene Expression Profiling Reveals Activation of Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis of Extranodal Nasal-Type NK/T Cell Lymphoma.. Blood, 2009, 114, 3931-3931. | 0.6 | 0 |
| 272 | MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.. Blood, 2009, 114, 834-834. | 0.6 | 0 |
| 273 | Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites. Blood, 2010, 116, 4160-4160. | 0.6 | 0 |
| 274 | The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML. Blood, 2010, 116, 4355-4355. | 0.6 | 0 |
| 275 | The Pro-Metastasis Tyrosine Phosphatase, PRL-3 (PTP4A3), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia. Blood, 2011, 118, 2741-2741. | 0.6 | 0 |
| 276 | A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia. Blood, 2011, 118, 1666-1666. | 0.6 | 0 |
| 277 | EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma. Blood, 2012, 120, 3498-3498. | 0.6 | 0 |
| 278 | Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. Blood, 2012, 120, 5035-5035. | 0.6 | 0 |
| 279 | Plasma Membrane Proteomics Identifies Biomarkers Associated with T(4;14) Multiple Myeloma. Blood, 2012, 120, 1314-1314. | 0.6 | 0 |
| 280 | cIg-FISH On Patients with Multiple Myeloma â€“ A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service. Blood, 2012, 120, 4792-4792. | 0.6 | 0 |
| 281 | A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma. Blood, 2013, 122, 4433-4433. | 0.6 | 0 |
| 282 | PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway. Blood, 2014, 124, 2093-2093. | 0.6 | 0 |
| 283 | MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents. Blood, 2014, 124, 171-171. | 0.6 | 0 |
| 284 | Incidence and Clinical Features of Calreticulin mutation in Patients with Jak2V617F-Negative Essential Thrombocytosis and Primary Myelofibrosis from Singapore. Blood, 2014, 124, 3176-3176. | 0.6 | 0 |
| 285 | Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma. Blood, 2015, 126, 3103-3103. | 0.6 | 0 |
| 286 | Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population. Blood, 2015, 126, 2574-2574. | 0.6 | 0 |
| 287 | Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712. | 0.6 | 0 |
| 288 | Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches. Blood, 2015, 126, 2764-2764. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis. Blood, 2016, 128, 4498-4498. | 0.6 | 0 |
| 290 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414. | 0.6 | 0 |
| 291 | Outcome and Prognostic Factors of Patients with Hematological Malignancies Admitted to an Intensive Care Unit. Blood, 2016, 128, 4796-4796. | 0.6 | 0 |
| 292 | Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL). Blood, 2016, 128, 1773-1773. | 0.6 | 0 |
| 293 | Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. Blood, 2016, 128, 4650-4650. | 0.6 | 0 |
| 294 | Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. Blood, 2018, 132, 3251-3251. | 0.6 | 0 |
| 295 | NSD2 Interacts with SMARCA2 and Regulates Expression of Oncogenes CCND1 and PRL3 in T(4;14) Multiple Myeloma. Blood, 2018, 132, 4479-4479. | 0.6 | 0 |
| 296 | Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies. Blood, 2018, 132, 5637-5637. | 0.6 | 0 |
| 297 | Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma. Blood, 2018, 132, 4513-4513. | 0.6 | 0 |
| 298 | Evaluation of Maintenance Therapy in Myeloma in an Asian Population. Blood, 2018, 132, 3231-3231. | 0.6 | 0 |
| 299 | Overexpressed Melk Promotes the Stability of EZH2 through Phosphorylation in Natural Killer/T Cell Lymphoma (NKTL). Blood, 2018, 132, 2858-2858. | 0.6 | 0 |
| 300 | Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma. Blood, 2019, 134, 5253-5253. | 0.6 | 0 |
| 301 | Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis. Blood, 2019, 134, 5177-5177. | 0.6 | 0 |
| 302 | Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE). Blood, 2019, 134, 5577-5577. | 0.6 | 0 |
| 303 | Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes. Blood, 2021, 138, 2653-2653. | 0.6 | 0 |
| 304 | Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma. Blood, 2021, 138, 2209-2209. | 0.6 | 0 |
| 305 | Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies. Blood, 2021, 138, 1678-1678. | 0.6 | 0 |
| 306 | Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience. Blood, 2021, 138, 1921-1921. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE). Blood, 2021, 138, 3045-3045. | 0.6 | 0 |
| 308 | Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study. Blood, 2021, 138, 720-720. | 0.6 | 0 |
| 309 | Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia. Blood, 2021, 138, 378-378. | 0.6 | 0 |
| 310 | The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. Blood, 2020, 136, 30-31. | 0.6 | 0 |
| 311 | Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. Blood, 2020, 136, 39-40. | 0.6 | 0 |
| 312 | T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. PLoS ONE, 2022, 17, e0261469. | 1.1 | 0 |
| 313 | Cancer in 2019 - Progress and Challenges - A Perspective. Annals of the Academy of Medicine, Singapore, 2019, 48, 45-47. | 0.2 | 0 |